On January 8, 2019 BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple cancer indications, reported that the Company will be presenting a corporate overview at the Biotech Showcase 2019 in San Francisco today at 10:00 am PST (Press release, BerGenBio, JAN 8, 2019, https://www.bergenbio.com/bergenbio-to-present-company-overview-at-biotech-showcase-2019-during-annual-j-p-morgan-conference-in-san-francisco/ [SID1234532590]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will webcast live and the presentation is available for download at the Company’s website: www.bergenbio.com/investors/presentations/
Details for the presentation are as follows:
Biotech Showcase
Date: Tuesday, January 8, 2019
Time: 10:00 am PST
Room: Franciscan A (Ballroom Level)
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street
END
Contact
Richard Godfrey, CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie, CFO, BerGenBio ASA
[email protected]
+47 917 86 513
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.